COMy 2022: Multiple myeloma roundup

Share :
Published: 24 May 2022
Views: 2675
Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Prof Philip Moreau speaks to ecancer about the key data presented at the Controversies in Multiple Myeloma 2022 meeting (COMy), held May 12-15th in Paris.

He starts off by updating us on the latest progression-free survival (PFS) and depth of response data in the phase 3 IKEMA trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) versus carfilzomib and dexamethasone (Kd) in relapsed multiple myeloma. This found that the median PFS with Isa-Kd was 35.7 months (95% CI, 25.8-44.0) vs 19.2 months (95% CI, 15.8-25.1) with Kd alone, converting to a 42% reduction in the risk of disease progression or death.

He then discusses a meta-analysis of ciltcabtagene autoleucel (CILTA-CEL) versus physician’s choice of treatment (PCT) for patients with relapsed or refractory multiple myeloma. Prof Moreau also touches on updates from cohort B of the CARTITUDE-2 study.

He talks about the efficacy and safety of ciltacabtagene autoleucel (CILTA-CEL) in lenalidomide-refractory patients with progressive multiple myeloma (MM) after 1–3 prior lines of therapy.

Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAXCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with R/R multiple myeloma are also mentioned.

He concludes by discussing the results from the MAJESTIC trial and the efficacy of cevostamab.

Updated analysis of IKEMA
Latest on CILTA-CEL
Progress on bispecific antibodies for treatment of multiple myeloma
Other promising immunotherapeutic treatment options
ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.